Carl L. Gordon, Director at Scribe Therapeutics, Inc. (SCTX), bought 1,000,000 shares at $15.00 ($15.0M) on 2026-07-27, disclosed to the SEC on 2026-07-29.
Director Carl L. Gordon purchased $15 million of Scribe Therapeutics stock at $15.00, marking the largest insider purchase in the company's history and signaling strong conviction in the stock's post-IPO momentum. This significant capital commitment comes as the stock has surged over 60% following its recent upsized IPO.
Scribe Therapeutics shares are currently trading at $18.46, representing a 27.05% discount from the 52-week high of $25.31 established on July 24, 2026, immediately following the company's successful $128.7 million upsized IPO.
1) Q3 2026 earnings on September 30, 2026; 2) The company's $125 million IPO proceeds are funding three clinical trials to test whether genetic editing can halve the risk of heart attacks and strokes, as reported on July 30, 2026; 3) Five other insiders bought shares in the last 30 days, indicating a cluster of insider support.
The stock is currently trading 6.31% above its 52-week low of $17.37, which could indicate that the recent post-IPO rally has already priced in significant optimism regarding the company's genetic editing therapies.
Nothing distinguishes this filing.
| Filing → |
| CMPX | SELL | 2025-04-11 | $11.4M | — | Filing → |
| MBX | BUY | 2025-02-19 | $2.7M | — | Filing → |
| MBX | BUY | 2024-09-17 | $12.0M | — | Filing → |